Epizyme sells Royalty Pharma future royalties on Japanese sales of tazemetostat
Epizyme Inc. assigned Royalty Pharma the future royalty streams on Japanese sales of tazemetostat (an oral EZH2 inhibitor candidate for both solid tumors and hematological malignancies). In exchange, Epizyme could receive as much as $570mm in financing, with up to a $200mm equity investment from Royalty Pharma and up to $370mm in debt financing from Pharmakon Advisors, a Royalty Pharma affiliate. Epizyme has appointed a representative from Royalty Pharma to its board.
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Nonconvertible Debt
- Royalty Sale
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com